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Background: Preconditioning and inhibition of sodium-proton exchange attenuate
myocardial ischemia-reperfusion injury by means of independent mechanisms that
might act additively when used together. The hypothesis of this study is that
treatment with a sodium-proton exchange inhibitor and a mitochondrial adenosine
triphosphate–sensitive potassium channel opener produces superior functional re-
covery and a greater decrease in left ventricular infarct size compared with treatment
with either drug alone in a model of severe global ischemia.
Methods: Isolated crystalloid-perfused rat hearts (n 8 hearts per group) were admin-
istered vehicle (control, 0.04% dimethyl sulfoxide), diazoxide (100 mol/L in 0.04%
dimethyl sulfoxide), cariporide (10 mol/L in 0.04% dimethyl sulfoxide), or diazoxide
and cariporide before 40 minutes of ischemia at 35.5°C to 36.5°C and 30 minutes of
reperfusion.
Results: The combination group had superior postischemic systolic function com-
pared with that seen in the cariporide, diazoxide, and control groups (recovery of
developed pressure: 91%  7% vs 26%  5%, 35%  6%, and 16%  3%,
respectively; P  .05). Postischemic diastolic function in the combination group
was superior compared with that seen in the other groups (changepre-post diastolic
pressure of 67  4 mm Hg with control, 49  11 mm Hg with diazoxide, 59  10
mm Hg with cariporide, and 3  3 mm Hg with diazoxide and cariporide combi-
nation; P  .05). The left ventricular infarct area was less in the combination group
compared with that in the cariporide, diazoxide, and control groups (6%  2% vs
35%  7%, 25%  3%, and 37%  9%, respectively; P  .05).
Conclusions: Combining a selective mitochondrial adenosine triphosphate–sensitive
potassium channel opener with a selective reversible inhibitor of sarcolemmal
sodium-proton exchange improves recovery of contractile function from severe
global ischemia in the isolated buffer-perfused rat heart. The putative mechanism for
this benefit is superior protection of mitochondrial function.
Ischemic preconditioning has been shown to improve cardiac functionalrecovery after ischemia and reperfusion. One postulated mechanism for thiseffect is modulation of mitochondrial adenosine triphosphate–sensitivepotassium (KATP) channels. Opening of this channel protects mitochon-dria, and thus the myocyte, from ischemia-reperfusion injury. Discovery ofmitochondrial KATP channel–mediated protection from ischemia-reperfu-
sion injury stimulated efforts to reproduce the protective effect of ischemic precon-
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ditioning by means of pharmacologic manipulation. Im-
proved postischemic mitochondrial and cardiac function
have now been demonstrated after treatment with drugs (eg,
diazoxide) that open mitochondrial KATP channels in iso-
lated hearts,1-5 isolated myocytes,6 isolated mitochondria,7
skinned myocardial bundles,8 and isolated human atrial
trabeculae.9
Pharmacologic inhibition of the sarcolemmal Na/H
exchanger during ischemia and reperfusion is another
pharmacologic means to reduce ischemia-reperfusion in-
jury.10 The benefit of Na/H exchange (NHE) inhibition
is based on limiting the net increase in intramyocyte Na
that results from sarcolemmal NHE during ischemia and
reperfusion. Attenuating this acute increase in cytosolic
Na in turn decreases the subsequent increase in myocyte
Ca caused by sarcolemmal Na/Ca exchange. NHE
inhibition is protective against ischemia-reperfusion in-
jury in the isolated heart,11-14 in intact pig hearts sup-
ported on cardiopulmonary bypass,15,16 and in a canine
infarct model.17
The mechanisms for the protective effects of NHE inhi-
bition and pharmacologic preconditioning mediated by mi-
tochondrial KATP channels are independent but have the
common end point of mitochondrial protection, which is
achieved either directly through opening of the KATP
channel or indirectly by sparing the mitochondria from
exposure to high cytosolic Ca. It is therefore possible
that combining these 2 methods will have an additive effect
that provides superior cardiac protection from ischemia-
reperfusion injury. We postulate that this protection is
achieved by limiting the flux of Ca into mitochondria
and by stabilizing the mitochondrial proton gradient against
changes caused by increased Ca.
Of note, one prior trial examined a combination of the
pharmacologic preconditioning agent diazoxide and the
NHE inhibitor cariporide in an isolated rabbit heart model
of regional ischemia-reperfusion injury. Cariporide alone
and diazoxide plus cariporide decreased infarct size mea-
sured as a percentage of the area at risk. However, no
protection was seen with diazoxide alone, and the combi-
nation of diazoxide and cariporide provided no added ben-
efit over that provided by cariporide alone.18 The absence of
a protective effect for diazoxide in this study, as well as the
variability that was present within each experimental group,
led us to question whether the absence of an additive effect
was a function of the experimental design.
The purpose of the present study was to determine
whether combining pretreatment with a sarcolemmal NHE
inhibitor and a mitochondrial KATP channel opener could
improve functional recovery and decrease the size of left
ventricular infarction in an isolated rat heart model of severe
global ischemia.
Methods
The investigation conformed to the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory An-
imal Resources, National Resource Council, and was approved by
the UAB Institutional Animal Care and Use Committee.
Isolated Heart Preparation
Rats weighing between 290 and 380 g were heparinized, and then
anesthesia was obtained with ketamine-xylazine, both adminis-
tered intraperitoneally. Hearts were removed, immersed in cold
buffer, and quickly cannulated and perfused through the aorta with
Krebs-Henseleit buffer, having a composition of NaCl (118 mmol/
L), KCl (4.7 mmol/L), CaCl2 (2.5 mmol/L), MgSO4 (1.2 mmol/L),
NaHCO3 (25 mmol/L), KH2PO4 (1.2 mmol/L), Na ethylenedia-
mine tetra-acetic acid (0.05 mmol/L), and glucose (11 mmol/L)
gassed with 95% oxygen and 5% carbon dioxide. A latex balloon
was inserted into the left ventricular cavity and anchored in place
with sutures. The hearts were immersed in buffer (35.5°C-36.5°C)
and paced. Perfusion pressure was maintained at 100 mm Hg by
using a custom-built perfusion system that permits perfusion at
either constant pressure or constant flow. The system, acting
through a stepper motor connected to a peristaltic pump, delivers
either a constant flow preset by the operator or provides a flow
sufficient to maintain a preset perfusion pressure. A constant-
pressure mode was used in this study.
Left Ventricular Pressure Recording
Left ventricular pressure waveforms, coronary flow, and coronary
perfusion pressures were measured and recorded on a laboratory
microcomputer and stored on the hard drive for later analysis.
Software determined diastolic and systolic pressures of the stored
data and measured positive and negative dP/dt, coronary vascular
resistance, and contracture time and force.
Area of Infarction
At the end of each experiment, hearts were perfused for an addi-
tional 2.5 hours; frozen, thawed, and sliced into 2-mm slices;
incubated in 1% triphenyl tetrazolium chloride for 20 minutes at
37°C; and fixed in formalin. The slices were pressed between glass
plates, and the total left ventricular area and unstained area (in-
farct) were traced. The tracings were enlarged with a copying
machine, and the areas were quantified with a computerized digi-
tizer.
Experimental Protocol
Each of 32 hearts from male rats were randomly assigned to one of
4 groups: a control group (vehicle only, 0.04% dimethyl sulfoxide
[DMSO]), a diazoxide group (100 mol/L diazoxide dissolved in
0.04% DMSO), a cariporide group (10 mol/L cariporide dis-
solved in 0.04% DMSO), and a combination group (100 mol/L
diazoxide plus 10 mol/L cariporide dissolved in 0.04% DMSO).
After a period of equilibration, using normal Krebs-Henseleit
buffer as a perfusate to ensure stability of the preparation, we made
initial recordings of pressure and flow. Hearts that did not have
developed pressures of 100 mm Hg or greater by the end of the
equilibration period were excluded from the study. End-diastolic
pressures ranged from 2 to 10 mm Hg, and developed pressures
ranged from 100 to 179 mm Hg. There were no differences
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between groups before treatment. After the pretreatment data ac-
quisition, the perfusate was switched to one of the 4 aforemen-
tioned groups, and perfusion was continued for 10 minutes with
pacing. At 10 minutes, pacing and perfusion were stopped (30
minutes of ischemia in the pilot study, n  3 hearts per group; 40
minutes of ischemia in the final study, n 8 hearts per group), and
the hearts were made globally ischemic. Temperature was main-
tained at 35.5°C to 36.5°C for the entire duration of ischemia.
At reperfusion, perfusion pressures were carefully controlled
because excessive perfusion pressures were found to be harmful to
postischemic hearts. Perfusion pressure was maintained at 60 mm
Hg for the first 15 minutes and then increased in increments of 10
mm Hg every 5 minutes. Pacing at 330 beats/min was resumed
when the perfusion pressure reached 100 mm Hg. At 30 minutes of
reperfusion, a final recording of cardiac function, coronary flow,
and perfusion pressure was made.
Diazoxide was obtained from Sigma Chemical Co (St Louis,
Mo). Cariporide was a generous gift from Aventis Pharma Deut-
schland GmbH (Frankfurt am Main, Germany).
Statistical Analysis
Analysis of stored waveform data included measurements of dia-
stolic and systolic pressures, positive and negative dP/dt, time to
peak pressure, diastolic decay time constant (), and coronary
vascular resistance. Results are shown as means  SEM.
The statistical design for the variables listed above is typical of
a longitudinal model with repeated measurements within an ex-
perimental unit over time and with the experimental units in
independent groups consisting of a control group and 3 drug
treatment groups. The data are balanced in the usual statistical
sense, with equal numbers of animals in each group. The data were
analyzed by using a fixed-effects repeated-measures analysis of
variance, with possible lack of independence in the measurements
within a subject being modeled with an unstructured covariance
matrix. Note that other possible models for the correlation struc-
ture were considered, but the unstructured covariance matrix gave
the best fit, as measured with likelihood ratio tests and the Akaike
criterion for model identification. The model contained effects for
group, time, and a group-by-time interaction. Least-squares means
were calculated for the group-by-time interactions, and multiple
comparisons were carried out with multicomparison adjustment by
using the Tukey method (SAS-PC version 8.00; SAS Institute Inc,
Cary, NC).
Infarct area was measured as a percentage of the area at risk.
Between-group comparisons of infarct area, time to contracture,
and force of contracture were done by using the Duncan multiple
range test (SAS-PC version 8.00, SAS Institute Inc).
Results
Initial (Pretreatment) Conditions
Developed pressures for the control, diazoxide, cariporide,
and combination groups were 137.6  7.1, 141.2  9.7,
142.9  6.0, and 140.0  8.2 mm Hg, respectively. End-
diastolic pressures for these groups were 4.4  0.3, 3.5 
0.5, 3.4  0.5, and 3.7  0.5 mm Hg, respectively. There
were no significant differences in developed pressures or
end-diastolic pressures among these groups. Coronary vas-
cular resistance was likewise similar among groups before
ischemia: 5.38  0.34, 5.25  0.36, 5.32  0.37, and
4.74  0.31 mm Hg  min1  mL1, respectively (Table
1).
TABLE 1A. Changes in function and coronary vascular resistance as a result of drug treatment before 40 minutes of
ischemia
Measurement time
Group Initial Treat Final
Developed pressure (mm Hg)
Control 137.59 6.65 119.64 6.57 21.55 4.09
Cariporide 142.89 5.57 132.55 6.92 34.45 6.05
Diazoxide 141.16 9.07 144.42 3.28 49.44 9.41
Combined 140.00 7.66 141.44 4.37 125.19 7.17
End-diastolic pressure (mm Hg)
Control 4.40 0.30 1.81 0.43 71.39 4.04
Cariporide 3.41 0.44 1.96 0.52 62.68 9.16
Diazoxide 3.48 0.47 2.06 0.23 52.01 10.25
Combined 3.73 0.47 1.39 0.63 6.98 2.68
Coronary vascular resistance (mm Hg  min1  mL1)
Control 5.38 0.32 5.56 0.25 7.54 1.09
Cariporide 5.32 0.34 6.18 0.42 5.94 0.47
Diazoxide 5.25 0.34 3.05 0.08 4.29 1.40
Combined 4.74 0.29 3.04 0.08 4.92 0.24
For each variable measured, longitudinal comparisons were made between the within-group values (initial, treatment, and final), and cross-sectional
comparisons were made between groups at each measurement time (Tables 1B-1D). These comparisons were made within the framework of a
repeated-measures analysis of variance that contained effects for group, time, and the group-by-time interaction and assumed an unstructured covariance
matrix for the within-subject lack of independence. In all cases the group-by-time interaction was found to be statistically significant (P  .0001). The
comparisons were made between the least-squares means, and the Tukey adjustment for multiple comparisons was used to determine the significance
level in all cases. Initial, Before drug; treat, after the drug was started and before ischemia; final, after ischemia.
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Effect of Preischemic Treatment
When comparing the pretreatment with posttreatment de-
veloped pressures within groups, developed pressures in the
control and cariporide groups decreased significantly,
whereas pressures in the diazoxide and combination groups
were unchanged (Table 1). There were no differences
among groups in end-diastolic pressure after preischemic
drug treatment, but within-group comparisons of end-dia-
stolic pressure showed significant decreases in the control
and cariporide groups. In both the diazoxide and the com-
bination groups, there were significant decreases in coro-
nary vascular resistance during the preischemic treatment
period, with no changes in the control and cariporide
groups.
Preliminary Studies With 30 Minutes of Ischemia
Preliminary studies with 30 minutes of global ischemia (n
3 hearts per group) showed a protective effect of diazoxide
and cariporide when used alone but failed to show a statis-
tically significant increment of protection with a combina-
tion of the drugs (Figure 1, A). The developed pressures in
control hearts recovered to 17.6%  5.6%, whereas the
treated groups had significantly better recovery (diazoxide,
78.5%  6.4%; cariporide, 76.4%  4.5%; combination,
TABLE 1B. Developed pressure within-group comparisons (P values)
Control Cariporide Diazoxide Combined
Treat Final Treat Final Treat Final Treat Final
Initial .0105 .0001 .049 .0001 .9999 .0001 .9999 .8813
Treat .0001 .0001 .0001 .1770
Cariporide Diazoxide Combined
Initial time point








Control .8226 .2688 .0001
Cariporide .9660 .0001
Diazoxide .0001
See footnote for Table 1A.
TABLE 1C. End-diastolic pressure within-group comparisons (P values)
Control Cariporide Diazoxide Combined
Treat Final Treat Final Treat Final Treat Final
Initial .0001 .0001 .0001 .0001 .3924 .0027 .1254 .9933
Treat .0001 .0001 .0016 .5343
Cariporide Diazoxide Combined
Initial time point








Control .9990 .8261 .0001
Cariporide .9996 .0002
Diazoxide .0095
See footnote for Table 1A.
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91.3%  9.3%; P  .05 vs control). The differences in
recovery of developed pressures between the combination
and single-drug groups did not attain statistical significance.
End-diastolic pressure in control hearts increased to 57.5 
5.1 mm Hg. The increase in diastolic pressure for the
combination and single-drug groups was significantly less
than that seen in the control group (diazoxide, 4.5 2.7 mm
Hg; cariporide, 5.3  2.6 mm Hg; combination, 2.5  2.0
mm Hg; P  .05 vs control; Figure 1, B). On the basis of
these observations, the ischemic interval was increased to
40 minutes for the subsequent experiments (n 8 hearts per
group) to magnify any potential protective effects of com-
bination therapy.
Studies With 40 Minutes of Ischemia
When the ischemic time was lengthened from 30 minutes to
40 minutes, protection by single drug treatment was lost,
whereas the combination treatment remained protective
(Table 1 and Figures 2 and 3). The percentage of recovery
of developed pressure after 40 minutes of global ischemia
was significantly better in hearts pretreated with the com-
bination of drugs compared with that seen in control hearts
(91.2% 6.6% combination vs 15.5% 3.2% control, P
.01; Figure 2, A). Diazoxide as sole therapy provided less
recovery of developed pressure (34.9%  6.1%, P  .27 vs
control). Similarly, recovery of developed pressure after
cariporide treatment alone was not significantly different
from recovery in the control group (P  .82 vs control).
Diastolic pressures increased by 67.0  4.1 mm Hg in
the control group, 48.5  10.9 mm Hg in the diazoxide
group, and 59.3  9.6 mm Hg in the cariporide group
(Figure 2, B). In the combination group the diastolic pres-
sure increase was only 3.3 3.2 mm Hg (P .01 vs control
or single-drug therapy).
Infarct areas, expressed as a percentage of the total left
ventricular area (Figure 3), were similar for the control
group (37.3%  9.1%), the diazoxide group (24.8% 
2.6%), and the cariporide group (34.7%  7.1%). In con-
trast, the infarct area was less in the combination group
(5.8% 1.8%, P .01 vs control and single-drug therapy).
During ischemia, contracture developed in all hearts. The
diazoxide-treated hearts had the longest contracture time
(21.5  1.3 minutes, P  .011) compared with that seen in
the other groups. The times to contracture for the control
and single-drug therapy groups ranged from 16.1 to 17.6
minutes and were not significantly different from each other
(Table 2). The force of contracture was greatest in the
cariporide and control groups (38.0  2.4 and 35.4  5.3
mm Hg, respectively) and was different from that seen in
the diazoxide and combination groups (24.5  1.7 and
20.3  1.7 mm Hg, respectively; P  .01 vs control and
cariporide groups).
Times to peak developed pressure during systole were no
different among groups before ischemia (range, 63.1-67.4
ms). These times lengthened after ischemia in all groups
(range, 67.2-75.3 ms), but the increases were insignificantly
different from each other.
The diastolic relaxation time constants () were similar
among groups before ischemia. Thirty minutes after reper-
fusion, they were significantly longer in the control group
than in each of the other treatment groups (Table 2). Al-
though the time constant was shortest in the combination
group, it was not statistically different from that seen in the
other treatment groups.
TABLE 1D. Coronary vascular resistance within-group comparisons
Control Cariporide Diazoxide Combined
Treat Final Treat Final Treat Final Treat Final
Initial .9639 .5324 .5387 .9477 .0001 .9999 .0001 .9989
Treat .6185 .9999 .9988 .0001
Cariporide Diazoxide Combined
Initial time point








Control .9650 .7893 .4754
Cariporide .9910 .7198
Diazoxide .9999
See footnote for Table 1A.
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After 30 minutes of reperfusion, the diazoxide group had
the lowest coronary vascular resistance compared with that
seen in the control group, although this comparison did not
attain significance (P  .79). The other groups were statis-
tically similar to the control group.
Discussion
These experiments show that in a Langendorff crystalloid-
perfused isolated rat heart model the combination of pre-
ischemic treatment with a sarcolemmal NHE inhibitor and a
mitochondrial KATP channel opener additively improves
systolic and diastolic functional recovery and limits infarct
area induced by 40 minutes of global ischemia. In the
preliminary study we observed that a combination of dia-
zoxide and cariporide provided an improvement that did not
attain statistical significance over each drug used alone as
protection from 30 minutes of normothermic ischemia.
When the ischemic interval was extended to 40 minutes for
the subsequent experiments, the protection provided by
diazoxide treatment was reduced, and the protection pro-
vided by cariporide was essentially lost. However, the com-
bination of diazoxide and cariporide afforded protection.
Postischemic diastolic pressures remained low after 30 min-
utes of ischemia in the single-drug treatment groups but
increased significantly after 40 minutes of ischemia. Com-
bination treatment prevented an increase in postischemic
diastolic pressure.
The additive beneficial effects of diazoxide and caripo-
ride on systolic and diastolic function confirm that the
Figure 1. A, Postischemic developed pressure as a percentage of
preischemic developed pressure for 30 minutes of ischemia. B,
Postischemic left ventricular end-diastolic pressure (in millime-
ters of mercury) for 30 minutes of ischemia. Con, Control; DZ,
diazoxide; Car, cariporide; Com, combination treatment.
Figure 2. A, Postischemic developed pressure as a percentage of
preischemic developed pressure for 40 minutes of ischemia. B,
Postischemic left ventricular end-diastolic pressure (in millime-
ters of mercury) for 40 minutes of ischemia. Con, Control; DZ,
diazoxide; Car, cariporide; Com, combination treatment.
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mechanisms for protection by NHE inhibition and mito-
chondrial KATP channel opening are independent and sug-
gest that they might have a common final effector. Diazox-
ide opens the mitochondrial KATP channel, thereby
partially depolarizing the mitochondrial membrane poten-
tial. This is thought to cause a decrease in the amount of
voltage-driven calcium uptake by injured mitochondria.19-22
Increases in mitochondrial calcium are injurious to mito-
chondria, although the precise mechanism for calcium-me-
diated mitochondrial injury has not been fully defined. De-
fining this mechanism at a molecular level in the
mitochondria is a long-range goal of this laboratory.
The highly selective NHE inhibitor cariporide limits
sodium uptake during ischemia and reperfusion, thereby
preventing excessive cytoplasmic calcium uptake through
the sarcolemmal sodium-calcium exchanger.23,24 We hy-
pothesize that diazoxide and cariporide can act additively to
improve myocyte ion homeostasis, thereby protecting mi-
tochondria from calcium-mediated injury. It is known that
an increase in cytoplasmic calcium can cause myofibrillar
hypercontracture,25 activation of cytoplasmic proteolytic
enzymes,26-28 and mitochondrial damage.29
In this study the test drugs were given before ischemia,
and this might not always be possible in clinical surgery.
However, cariporide and diazoxide still have an effect in
controlling calcium uptake when given only during reper-
fusion.8,16 Thus this limitation diminishes but does not elim-
inate the usefulness of combination therapy in situations in
which ischemia starts before the drugs can be given. The
asanguineous perfusate used in this study is another limita-
tion because it does not perfectly mimic the clinical situa-
tion, in which leukocytes contribute to reperfusion injury.
Parallel studies in an intact porcine model are underway in
this laboratory to validate the findings from the rat studies.
Relaxation time constants, which are an index of active
diastolic relaxation,30 were significantly increased in the
control group after ischemia (P  .01), marginally in-
creased in the diazoxide group (P  .056), increased in the
cariporide group (P  .027), and unchanged in the combi-
nation treatment group (P  .186). Impairment of diastolic
relaxation might be caused by ischemic injury to the sarco-
plasmic reticulum. This injury is presumably most severe in
the case of the control hearts and results in decreased
calcium uptake rates during diastole. The combination of
cariporide and diazoxide might improve protection of the
sarcoplasmic reticulum compared with protection provided
by each drug alone.
Infarct areas were measured in the hearts with 40 min-
utes of ischemia. The global ischemic injury produced
patchy areas of necrosis in the control hearts, as well as in
the diazoxide- and cariporide-treated hearts. These areas of
infarction were significantly decreased in size when diazox-
ide and cariporide were combined as preischemic treatment.
The combination of diazoxide and cariporide was previ-
ously examined in an intact rabbit model of regional isch-
emia and infarction, but no significant reduction in infarct
size was observed.18 The reason for the discrepancy be-
tween our results and these other results is not clear but
could be due to the difference in species, to the fact that the
intact rabbit hearts were blood perfused while our hearts
were buffer perfused, or to the effective final concentration
of agents at the myocyte level. It has been observed that
diazoxide binds immediately to plasma proteins, thus de-
creasing the effective concentration.31 Our study indicates
that an additive beneficial effect exists and justifies further
investigation of combination therapy, including dose-re-
sponse studies and experiments to confirm the putative
mechanisms for its benefit.
Another issue is the effect of changes in coronary vas-
cular resistance and flow on recovery of cardiac function.









Control 16.8 1.6 35.4 5.3 410 108
Diazoxide 21.5 1.3* 24.5 2.0† 126 55†
Cariporide 16.1 0.9 38.0 2.4 111 35†
Combination 17.6 0.8 20.3 1.7* 3.4 2.3†
All values are given as means  SEM.
*P  .05 and †P  .01 compared with the control group (n  8 hearts per
group).
Figure 3. Infarct area as a percentage of left ventricular area (ie,
area at risk in global ischemia) for 40 minutes of ischemia. Con,
Control; DZ, diazoxide; Car, cariporide; Com, combination treat-
ment.
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The diazoxide group had significantly lower coronary vas-
cular resistance than the cariporide or control groups, but
recovery of systolic and diastolic function in the diazoxide
group was significantly less than in the combination group.
Thus the improved functional recovery we observed in the
combination-treated hearts was not solely due to an increase
in coronary flow during reperfusion.
The concept of combining NHE inhibition with isch-
emic or pharmacologic preconditioning to improve re-
covery from ischemia is not new, although the mecha-
nisms for an additive benefit have not been determined,
and methods for clinical use of this information have not
been developed. Other combinations that have been stud-
ied include ischemic preconditioning and the NHE1 in-
hibitor BIIB 513,24 ischemic preconditioning and ethyli-
sopropylamiloride (another NHE inhibitor),32,33 and
ischemic preconditioning and cariporide.1 Sato and col-
leagues34 combined adenosine and diazoxide in a cellular
model of simulated ischemia. In each of these studies,
recovery of function was improved, and infarct area was
reduced or cell survival was increased when the combi-
nation was used.
The present study indicates that pharmacologic pre-
conditioning with a selective mitochondrial KATP chan-
nel opener (diazoxide) acts additively with NHE inhibi-
tion to provide protection from severe ischemia-
reperfusion injury. Thus our findings, if confirmed in
studies using more clinically relevant models, will sup-
port the use of drugs that are in preclinical or clinical
development (eg, nicorandil [a sarcolemmal and mito-
chondrial KATP channel opener] and cariporide) as com-
bination therapy to treat ischemia-reperfusion injury in
cardiac surgery. Moreover, the findings suggest that the
mechanism for this additive protection is improved pro-
tection of myocyte ion homeostasis and mitochondrial
function during ischemia and reperfusion. This putative
mechanism provides the basis for further development of
novel methods for mitochondrial and myocardial protec-
tion that might, in the future, be useful for treating severe
ischemia-reperfusion injury in cardiac surgery.
In summary, we have shown that combining a selec-
tive mitochondrial KATP channel opener with a selective
reversible inhibitor of sarcolemmal NHE decreases in-
farct size and improves recovery of systolic and diastolic
contractile function after severe global ischemia in the
isolated buffer-perfused rat heart. We hypothesize that
the simultaneous application of these 2 drugs before
ischemia not only limits the total gain in cytoplasmic
calcium with ischemia and reperfusion but also limits the
gain in calcium by the mitochondria, thereby improving
mitochondrial function and thus enhancing energy pro-
duction.
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